Read

Articles

Biomarker explainers, longevity research and product updates — in one feed.

ResearchMedicine and treatment
Health news, 18 October 2026: tucatinib maintenance in HER2-positive breast cancer, an oral GLP-1 tablet in Europe, alternatives to patching for amblyopia, and an oral TREM2 drug for Alzheimer's
Four events from 7 to 16 October: FDA approval of tucatinib as maintenance treatment in advanced HER2-positive breast cancer, an EMA recommendation for the once-daily GLP-1 tablet orforglipron, a meta-analysis of 11 trials of alternatives to patching in childhood amblyopia, and a phase 1 trial of an oral TREM2 activator for Alzheimer's disease.
18 October 20265 min read
ResearchMedicine and treatment
Health news, 16 October 2026: an FDA approval in dMMR colon cancer, an oral IL-23 blocker, and a microRNA model after a positive FIT
Five events from the past two weeks: FDA approval of atezolizumab after surgery for stage III dMMR colon cancer, a phase 2 NEJM trial of oral icotrokinra in ulcerative colitis, a plasma microRNA model after a positive FIT, leg alignment after ACL surgery in teenagers, and biological age in 326,000 people.
16 October 20268 min read
ResearchMedicine and treatment
Stem-cell neurons for Parkinson's disease: what the first human trials measured
In 2025 two small trials grafted dopamine-producing cells grown from stem cells into people with Parkinson's disease. What they measured, in whom, why fetal-tissue grafts failed under sham control, and what the phase 3 trial now has to show.
14 October 20268 min read
ResearchMedicine and treatment
Daily multivitamins for years: what the large randomized trials found
Two large trials followed people on a daily multivitamin for 3.6 and 11.2 years. Cancer incidence was slightly lower in older men but not in the trial that included women; heart attacks, strokes and deaths did not change; memory results disagree. What the data say about taking vitamins all year round.
9 October 202611 min read
ResearchMedicine and treatment
mRNA vaccines after COVID: what the flu, RSV and cancer trials measured
A seasonal mRNA flu shot measured against the standard-dose vaccine, an RSV dose whose efficacy fell as follow-up lengthened, and two cancer programmes that were only ever given after surgery. What each trial measured, in whom, and over how long.
6 October 20268 min read
ResearchMedicine and treatment
New antibiotics for resistant bacteria: what the trials actually measured
Gepotidacin, zoliflodacin, zosurabalpin and sulbactam-durlobactam are four drugs for three different bacteria at three different levels of evidence. What each trial measured, in whom, and why the circulating "90.1% cure" figure has no trial behind it.
6 October 20268 min read
ResearchMedicine and treatment
Approved Gene Therapy: Who Qualifies, How Long It Has Been Followed, What Is Known About Harm
Six one-time genetic treatments are licensed in the United States for sickle cell disease, beta-thalassemia, hemophilia and SMA. What the labels say about eligibility, how many years anyone has actually been followed, and what the boxed warnings record.
6 October 202612 min read
ResearchMedicine and treatment
CAR-T Beyond Cancer: What "Drug-Free Remission" Measured in Lupus, Myositis and Scleroderma
Cell therapies built for blood cancers have put a few dozen people with refractory lupus, myositis and systemic sclerosis into drug-free remission — in case series and phase 1 trials. How many exactly, which remission standard, how long the follow-up — and why none of it is a treatment option yet.
6 October 202610 min read
ResearchMedicine and treatment
One infusion, a permanent edit: what gene editing for cholesterol has measured so far
VERVE-102 and CTX310 edit liver genes to lower LDL cholesterol after a single infusion. The 2026 papers report large drops in a few dozen selected patients — open-label, no placebo, and not one cardiovascular event counted.
6 October 20268 min read
ResearchMedicine and treatment
Lp(a) as a drug target: what the trials have measured, and what they have not
Four investigational drugs lower lipoprotein(a) sharply in phase 2 trials. In September 2026 the first trial that counted heart attacks and strokes missed its endpoint. What was measured, on whom, and what the result does not settle.
6 October 20268 min read
ResearchMedicine and treatment
Wet macular degeneration: what the trials show about eye injections, longer intervals and the newest drugs
Anti-VEGF injections have preserved vision in large randomised trials of regular treatment. Newer drugs and an implant were shown to be no worse at longer intervals, each with its own safety profile; the latest phase 3 results are still company-reported.
5 October 20268 min read
ResearchMedicine and treatment
A statin delivered into the plaque: why rosuvastatin was packed into a fat capsule
YN001 is an experimental liposomal rosuvastatin that tries to deliver a statin straight into atherosclerotic plaque via the CD44 protein. The idea, the early data, the phase 2b PURIFY-TIMI 81 trial, and what it does not yet mean.
3 October 20263 min read

Articles in this section are educational and are not medical advice, a diagnosis, or a prescription. Consult a qualified professional before acting on anything you read here.

Loading Lonevi

Please wait while we prepare your medical assistant...

Health news, 18 October 2026: tucatinib maintenance in HER2-positive breast cancer, an oral GLP-1 tablet in Europe, alternatives to patching for amblyopia, and an oral TREM2 drug for Alzheimer's

Health news, 16 October 2026: an FDA approval in dMMR colon cancer, an oral IL-23 blocker, and a microRNA model after a positive FIT

Stem-cell neurons for Parkinson's disease: what the first human trials measured

Daily multivitamins for years: what the large randomized trials found

mRNA vaccines after COVID: what the flu, RSV and cancer trials measured

New antibiotics for resistant bacteria: what the trials actually measured

Approved Gene Therapy: Who Qualifies, How Long It Has Been Followed, What Is Known About Harm

CAR-T Beyond Cancer: What "Drug-Free Remission" Measured in Lupus, Myositis and Scleroderma

One infusion, a permanent edit: what gene editing for cholesterol has measured so far

Lp(a) as a drug target: what the trials have measured, and what they have not

Wet macular degeneration: what the trials show about eye injections, longer intervals and the newest drugs

A statin delivered into the plaque: why rosuvastatin was packed into a fat capsule